ID   PLCG2_HUMAN             Reviewed;        1265 AA.
AC   P16885; D3DUL3; Q3ZTS2; Q59H45; Q969T5;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 4.
DT   10-MAY-2017, entry version 202.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2;
DE            EC=3.1.4.11;
DE   AltName: Full=Phosphoinositide phospholipase C-gamma-2;
DE   AltName: Full=Phospholipase C-IV;
DE            Short=PLC-IV;
DE   AltName: Full=Phospholipase C-gamma-2;
DE            Short=PLC-gamma-2;
GN   Name=PLCG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymphoblast;
RX   PubMed=2849563; DOI=10.1016/0014-5793(88)80979-7;
RA   Ohta S., Matsui A., Nazawa Y., Kagawa Y.;
RT   "Complete cDNA encoding a putative phospholipase C from transformed
RT   human lymphocytes.";
RL   FEBS Lett. 242:31-35(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=16533400; DOI=10.1186/1471-2164-7-48;
RA   Kemmer D., Podowski R.M., Arenillas D., Lim J., Hodges E., Roth P.,
RA   Sonnhammer E.L.L., Hoeoeg C., Wasserman W.W.;
RT   "NovelFam3000 -- uncharacterized human protein domains conserved
RT   across model organisms.";
RL   BMC Genomics 7:48-48(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-244 AND
RP   TYR-883.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION AT TYR-753 AND TYR-759.
RX   PubMed=11606584; DOI=10.1074/jbc.M107577200;
RA   Rodriguez R., Matsuda M., Perisic O., Bravo J., Paul A., Jones N.P.,
RA   Light Y., Swann K., Williams R.L., Katan M.;
RT   "Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme
RT   function in B-cell signaling.";
RL   J. Biol. Chem. 276:47982-47992(2001).
RN   [8]
RP   PHOSPHORYLATION AT TYR-753 AND TYR-759.
RX   PubMed=12181444; DOI=10.1124/mol.62.3.672;
RA   Ozdener F., Dangelmaier C., Ashby B., Kunapuli S.P., Daniel J.L.;
RT   "Activation of phospholipase Cgamma2 by tyrosine phosphorylation.";
RL   Mol. Pharmacol. 62:672-679(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1245, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-753; TYR-759 AND
RP   TYR-1217, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   INVOLVEMENT IN FCAS3.
RX   PubMed=22236196; DOI=10.1056/NEJMoa1102140;
RA   Ombrello M.J., Remmers E.F., Sun G., Freeman A.F., Datta S.,
RA   Torabi-Parizi P., Subramanian N., Bunney T.D., Baxendale R.W.,
RA   Martins M.S., Romberg N., Komarow H., Aksentijevich I., Kim H.S.,
RA   Ho J., Cruse G., Jung M.Y., Gilfillan A.M., Metcalfe D.D., Nelson C.,
RA   O'Brien M., Wisch L., Stone K., Douek D.C., Gandhi C., Wanderer A.A.,
RA   Lee H., Nelson S.F., Shianna K.V., Cirulli E.T., Goldstein D.B.,
RA   Long E.O., Moir S., Meffre E., Holland S.M., Kastner D.L., Katan M.,
RA   Hoffman H.M., Milner J.D.;
RT   "Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2
RT   deletions.";
RL   N. Engl. J. Med. 366:330-338(2012).
RN   [13]
RP   VARIANT APLAID TYR-707.
RX   PubMed=23000145; DOI=10.1016/j.ajhg.2012.08.006;
RA   Zhou Q., Lee G.S., Brady J., Datta S., Katan M., Sheikh A.,
RA   Martins M.S., Bunney T.D., Santich B.H., Moir S., Kuhns D.B.,
RA   Long Priel D.A., Ombrello A., Stone D., Ombrello M.J., Khan J.,
RA   Milner J.D., Kastner D.L., Aksentijevich I.;
RT   "A hypermorphic missense mutation in PLCG2, encoding phospholipase
RT   Cgamma2, causes a dominantly inherited autoinflammatory disease with
RT   immunodeficiency.";
RL   Am. J. Hum. Genet. 91:713-720(2012).
RN   [14]
RP   VARIANTS TRP-665 AND PHE-845.
RX   PubMed=24869598; DOI=10.1056/NEJMoa1400029;
RA   Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M.,
RA   Ruppert A.S., Xue L., Li D.H., Steggerda S.M., Versele M., Dave S.S.,
RA   Zhang J., Yilmaz A.S., Jaglowski S.M., Blum K.A., Lozanski A.,
RA   Lozanski G., James D.F., Barrientos J.C., Lichter P., Stilgenbauer S.,
RA   Buggy J.J., Chang B.Y., Johnson A.J., Byrd J.C.;
RT   "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor
RT   ibrutinib.";
RL   N. Engl. J. Med. 370:2286-2294(2014).
CC   -!- FUNCTION: The production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is
CC       mediated by activated phosphatidylinositol-specific phospholipase
CC       C enzymes. It is a crucial enzyme in transmembrane signaling.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate +
CC       diacylglycerol.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- SUBUNIT: Interacts (via SH2 domain) with CSF1R (tyrosine
CC       phosphorylated). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=6; IntAct=EBI-617403, EBI-608057;
CC       P00533:EGFR; NbExp=5; IntAct=EBI-617403, EBI-297353;
CC       P19235:EPOR; NbExp=3; IntAct=EBI-617403, EBI-617321;
CC       P04626:ERBB2; NbExp=3; IntAct=EBI-617403, EBI-641062;
CC       O95073-2:FSBP; NbExp=2; IntAct=EBI-617403, EBI-10696047;
CC       Q13480:GAB1; NbExp=15; IntAct=EBI-617403, EBI-517684;
CC       P10721:KIT; NbExp=8; IntAct=EBI-617403, EBI-1379503;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-617403, EBI-79464;
CC       O43242:PSMD3; NbExp=2; IntAct=EBI-617403, EBI-357622;
CC       O14796:SH2D1B; NbExp=2; IntAct=EBI-617403, EBI-3923013;
CC   -!- PTM: Phosphorylated on tyrosine residues by CSF1R (By similarity).
CC       Phosphorylated on tyrosine residues by BTK and SYK; upon ligand-
CC       induced activation of a variety of growth factor receptors and
CC       immune system receptors. Phosphorylation leads to increased
CC       phospholipase activity. {ECO:0000250, ECO:0000269|PubMed:11606584,
CC       ECO:0000269|PubMed:12181444}.
CC   -!- DISEASE: Familial cold autoinflammatory syndrome 3 (FCAS3)
CC       [MIM:614468]: An autosomal dominant immune disorder characterized
CC       by the development of cutaneous urticaria, erythema, and pruritis
CC       in response to cold exposure. Affected individuals have variable
CC       additional immunologic defects, including antibody deficiency,
CC       decreased numbers of B-cells, defective B-cells, increased
CC       susceptibility to infection, and increased risk of autoimmune
CC       disorders. {ECO:0000269|PubMed:22236196}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Autoinflammation, antibody deficiency, and immune
CC       dysregulation PLCG2-associated (APLAID) [MIM:614878]: An autosomal
CC       dominant systemic disorder characterized by recurrent blistering
CC       skin lesions with a dense inflammatory infiltrate and variable
CC       involvement of other tissues, including joints, the eye, and the
CC       gastrointestinal tract. Affected individuals have a mild humoral
CC       immune deficiency associated with recurrent sinopulmonary
CC       infections, but no evidence of circulating autoantibodies.
CC       {ECO:0000269|PubMed:23000145}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60112.1; Type=Frameshift; Positions=1242; Evidence={ECO:0000305};
CC       Sequence=AAQ76815.1; Type=Frameshift; Positions=1242; Evidence={ECO:0000305};
CC       Sequence=BAD92151.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAA32194.1; Type=Frameshift; Positions=1242; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M37238; AAA60112.1; ALT_FRAME; mRNA.
DR   EMBL; X14034; CAA32194.1; ALT_FRAME; mRNA.
DR   EMBL; AB208914; BAD92151.1; ALT_INIT; mRNA.
DR   EMBL; AY364256; AAQ76815.1; ALT_FRAME; mRNA.
DR   EMBL; AC092142; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC098966; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC099524; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471114; EAW95524.1; -; Genomic_DNA.
DR   EMBL; CH471114; EAW95525.1; -; Genomic_DNA.
DR   EMBL; BC007565; AAH07565.1; -; mRNA.
DR   EMBL; BC011772; AAH11772.1; -; mRNA.
DR   EMBL; BC014561; AAH14561.1; -; mRNA.
DR   EMBL; BC018646; AAH18646.1; -; mRNA.
DR   CCDS; CCDS42204.1; -.
DR   PIR; S02004; S02004.
DR   RefSeq; NP_002652.2; NM_002661.4.
DR   UniGene; Hs.372303; -.
DR   UniGene; Hs.413111; -.
DR   UniGene; Hs.586906; -.
DR   PDB; 2K2J; NMR; -; A=471-913.
DR   PDB; 2W2W; X-ray; 3.30 A; A/B/C/D/E/F/G/H/I/J/K/L=471-913.
DR   PDB; 2W2X; X-ray; 2.30 A; C/D=471-913.
DR   PDBsum; 2K2J; -.
DR   PDBsum; 2W2W; -.
DR   PDBsum; 2W2X; -.
DR   ProteinModelPortal; P16885; -.
DR   SMR; P16885; -.
DR   BioGrid; 111352; 41.
DR   IntAct; P16885; 37.
DR   MINT; MINT-1199011; -.
DR   STRING; 9606.ENSP00000352336; -.
DR   BindingDB; P16885; -.
DR   ChEMBL; CHEMBL4100; -.
DR   GuidetoPHARMACOLOGY; 1408; -.
DR   SwissLipids; SLP:000000647; -.
DR   iPTMnet; P16885; -.
DR   PhosphoSitePlus; P16885; -.
DR   BioMuta; PLCG2; -.
DR   DMDM; 215274231; -.
DR   EPD; P16885; -.
DR   MaxQB; P16885; -.
DR   PaxDb; P16885; -.
DR   PeptideAtlas; P16885; -.
DR   PRIDE; P16885; -.
DR   DNASU; 5336; -.
DR   Ensembl; ENST00000564138; ENSP00000482457; ENSG00000197943.
DR   GeneID; 5336; -.
DR   KEGG; hsa:5336; -.
DR   UCSC; uc002fgt.4; human.
DR   CTD; 5336; -.
DR   DisGeNET; 5336; -.
DR   GeneCards; PLCG2; -.
DR   HGNC; HGNC:9066; PLCG2.
DR   HPA; CAB004280; -.
DR   HPA; HPA020099; -.
DR   HPA; HPA020100; -.
DR   MalaCards; PLCG2; -.
DR   MIM; 600220; gene.
DR   MIM; 614468; phenotype.
DR   MIM; 614878; phenotype.
DR   neXtProt; NX_P16885; -.
DR   OpenTargets; ENSG00000197943; -.
DR   Orphanet; 324530; Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.
DR   Orphanet; 300359; PLCG2-associated antibody deficiency and immune dysregulation.
DR   PharmGKB; PA33393; -.
DR   eggNOG; KOG1264; Eukaryota.
DR   eggNOG; ENOG410XPXE; LUCA.
DR   GeneTree; ENSGT00730000110782; -.
DR   HOGENOM; HOG000230864; -.
DR   HOVERGEN; HBG053611; -.
DR   InParanoid; P16885; -.
DR   KO; K05859; -.
DR   OMA; MLMRIPR; -.
DR   OrthoDB; EOG091G07R3; -.
DR   PhylomeDB; P16885; -.
DR   TreeFam; TF313216; -.
DR   BioCyc; MetaCyc:HS06773-MONOMER; -.
DR   BRENDA; 3.1.4.11; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-166016; Toll Like Receptor 4 (TLR4) Cascade.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5621480; Dectin-2 family.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P16885; -.
DR   SIGNOR; P16885; -.
DR   EvolutionaryTrace; P16885; -.
DR   GeneWiki; PLCG2; -.
DR   GenomeRNAi; 5336; -.
DR   PRO; PR:P16885; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000197943; -.
DR   CleanEx; HS_PLCG2; -.
DR   ExpressionAtlas; P16885; baseline and differential.
DR   Genevisible; P16885; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0004629; F:phospholipase C activity; TAS:Reactome.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0004871; F:signal transducer activity; IEA:UniProtKB-KW.
DR   GO; GO:0032237; P:activation of store-operated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; NAS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0002316; P:follicular B cell differentiation; IEA:Ensembl.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0032959; P:inositol trisphosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IEA:Ensembl.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; TAS:UniProtKB.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR016279; PLC-gamma.
DR   InterPro; IPR028381; PLC-gamma2.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF128; PTHR10336:SF128; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PIRSF; PIRSF000952; PLC-gamma; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF51695; SSF51695; 2.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Disease mutation; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; SH2 domain; SH3 domain; Transducer.
FT   CHAIN         1   1265       1-phosphatidylinositol 4,5-bisphosphate
FT                                phosphodiesterase gamma-2.
FT                                /FTId=PRO_0000088501.
FT   DOMAIN       20    131       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      312    456       PI-PLC X-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00270}.
FT   DOMAIN      532    635       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      646    735       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      769    829       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      930   1044       PI-PLC Y-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00271}.
FT   DOMAIN     1059   1152       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   ACT_SITE    327    327       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   ACT_SITE    372    372       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   MOD_RES     753    753       Phosphotyrosine; by BTK.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:11606584,
FT                                ECO:0000269|PubMed:12181444}.
FT   MOD_RES     759    759       Phosphotyrosine; by BTK.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:11606584,
FT                                ECO:0000269|PubMed:12181444}.
FT   MOD_RES    1197   1197       Phosphotyrosine; by BTK. {ECO:0000250}.
FT   MOD_RES    1217   1217       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1245   1245       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15144186}.
FT   VARIANT     244    244       H -> R (in dbSNP:rs11548656).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_031560.
FT   VARIANT     268    268       R -> W (in dbSNP:rs1143687).
FT                                /FTId=VAR_031561.
FT   VARIANT     541    541       T -> A (in dbSNP:rs11548657).
FT                                /FTId=VAR_047427.
FT   VARIANT     665    665       R -> W (found in patients with chronic
FT                                lymphocytic leukemia; associated with BTK
FT                                mutation S-481; unknown pathological
FT                                significance; results in resistance to
FT                                ibrutinib therapy).
FT                                {ECO:0000269|PubMed:24869598}.
FT                                /FTId=VAR_074310.
FT   VARIANT     707    707       S -> Y (in APLAID; results in increased
FT                                epidermal growth factor-stimulated
FT                                production of intracellular IP3 and
FT                                increased intracellular calcium release;
FT                                is a hypermorphic mutation;
FT                                dbSNP:rs397514562).
FT                                {ECO:0000269|PubMed:23000145}.
FT                                /FTId=VAR_069211.
FT   VARIANT     845    845       L -> F (found in patients with chronic
FT                                lymphocytic leukemia; associated with BTK
FT                                mutation S-481; unknown pathological
FT                                significance; results in resistance to
FT                                ibrutinib therapy).
FT                                {ECO:0000269|PubMed:24869598}.
FT                                /FTId=VAR_074311.
FT   VARIANT     883    883       D -> Y (in dbSNP:rs17856213).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047428.
FT   CONFLICT    606    610       TFSSI -> RFRRM (in Ref. 1; CAA32194/
FT                                AAA60112 and 3; AAQ76815). {ECO:0000305}.
FT   CONFLICT    623    623       R -> P (in Ref. 1; AAA60112/CAA32194 and
FT                                3; AAQ76815). {ECO:0000305}.
FT   CONFLICT    745    745       M -> T (in Ref. 1; AAA60112/CAA32194 and
FT                                3; AAQ76815). {ECO:0000305}.
FT   CONFLICT    880    880       Q -> E (in Ref. 1; AAA60112/CAA32194 and
FT                                3; AAQ76815). {ECO:0000305}.
FT   CONFLICT    912    912       T -> S (in Ref. 1; AAA60112/CAA32194 and
FT                                3; AAQ76815). {ECO:0000305}.
FT   CONFLICT   1095   1095       D -> G (in Ref. 1; AAA60112/CAA32194 and
FT                                3; AAQ76815). {ECO:0000305}.
FT   STRAND      478    485       {ECO:0000244|PDB:2W2X}.
FT   TURN        486    489       {ECO:0000244|PDB:2W2X}.
FT   STRAND      490    499       {ECO:0000244|PDB:2W2X}.
FT   STRAND      502    505       {ECO:0000244|PDB:2W2X}.
FT   HELIX       509    514       {ECO:0000244|PDB:2W2X}.
FT   STRAND      850    854       {ECO:0000244|PDB:2W2X}.
FT   HELIX       855    857       {ECO:0000244|PDB:2W2X}.
FT   STRAND      858    862       {ECO:0000244|PDB:2W2X}.
FT   STRAND      867    869       {ECO:0000244|PDB:2K2J}.
FT   STRAND      870    882       {ECO:0000244|PDB:2W2X}.
FT   STRAND      886    892       {ECO:0000244|PDB:2W2X}.
FT   HELIX       893    907       {ECO:0000244|PDB:2W2X}.
SQ   SEQUENCE   1265 AA;  147870 MW;  1D56BCBF51D7A0D3 CRC64;
     MSTTVNVDSL AEYEKSQIKR ALELGTVMTV FSFRKSTPER RTVQVIMETR QVAWSKTADK
     IEGFLDIMEI KEIRPGKNSK DFERAKAVRQ KEDCCFTILY GTQFVLSTLS LAADSKEDAV
     NWLSGLKILH QEAMNASTPT IIESWLRKQI YSVDQTRRNS ISLRELKTIL PLINFKVSSA
     KFLKDKFVEI GAHKDELSFE QFHLFYKKLM FEQQKSILDE FKKDSSVFIL GNTDRPDASA
     VYLHDFQRFL IHEQQEHWAQ DLNKVRERMT KFIDDTMRET AEPFLFVDEF LTYLFSRENS
     IWDEKYDAVD MQDMNNPLSH YWISSSHNTY LTGDQLRSES SPEAYIRCLR MGCRCIELDC
     WDGPDGKPVI YHGWTRTTKI KFDDVVQAIK DHAFVTSSFP VILSIEEHCS VEQQRHMAKA
     FKEVFGDLLL TKPTEASADQ LPSPSQLREK IIIKHKKLGP RGDVDVNMED KKDEHKQQGE
     LYMWDSIDQK WTRHYCAIAD AKLSFSDDIE QTMEEEVPQD IPPTELHFGE KWFHKKVEKR
     TSAEKLLQEY CMETGGKDGT FLVRESETFP NDYTLSFWRS GRVQHCRIRS TMEGGTLKYY
     LTDNLTFSSI YALIQHYRET HLRCAEFELR LTDPVPNPNP HESKPWYYDS LSRGEAEDML
     MRIPRDGAFL IRKREGSDSY AITFRARGKV KHCRINRDGR HFVLGTSAYF ESLVELVSYY
     EKHSLYRKMR LRYPVTPELL ERYNMERDIN SLYDVSRMYV DPSEINPSMP QRTVKALYDY
     KAKRSDELSF CRGALIHNVS KEPGGWWKGD YGTRIQQYFP SNYVEDISTA DFEELEKQII
     EDNPLGSLCR GILDLNTYNV VKAPQGKNQK SFVFILEPKQ QGDPPVEFAT DRVEELFEWF
     QSIREITWKI DTKENNMKYW EKNQSIAIEL SDLVVYCKPT SKTKDNLENP DFREIRSFVE
     TKADSIIRQK PVDLLKYNQK GLTRVYPKGQ RVDSSNYDPF RLWLCGSQMV ALNFQTADKY
     MQMNHALFSL NGRTGYVLQP ESMRTEKYDP MPPESQRKIL MTLTVKVLGA RHLPKLGRSI
     ACPFVEVEIC GAEYDNNKFK TTVVNDNGLS PIWAPTQEKV TFEIYDPNLA FLRFVVYEED
     MFSDPNFLAH ATYPIKAVKS GFRSVPLKNG YSEDIELASL LVFCEMRPVL ESEEELYSSC
     RQLRRRQEEL NNQLFLYDTH QNLRNANRDA LVKEFSVNEN QLQLYQEKCN KRLREKRVSN
     SKFYS
//
